Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC42H45N7O12S2 |
InChIKeyLOLHUPGCPDURJG-UHFFFAOYSA-N |
CAS Registry2097971-01-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 18 Apr 2017 | |
Neoplasms | Preclinical | United States | 18 Apr 2017 |